"Mono-(2-ethylhexyl) phthalate (MEHP), a DEHP metabolite, activates peroxisome proliferator-activated receptor(PPAR) g transcription more selectively than rosglitazone, a drug used to treat type 2 diabetes by increasing insulin sensitivity. This selective upregulation appears to explain the differential effects of rosglitazone and MEHP, in which MEHP produces a phenotype of insulin resistance in cellular models,[14,15] and in vivo. Given that PPAR plays key roles in lipid and carbohydrate metabolism, these ﬁndings provide biological plausibility for DEHP metabolites in insulin resistance. ..."
"Di-2-ethylhexylphthalate (DEHP) is an environmental chemical commonly found in processed foods [and food packaging]. Phthalate exposures, in particular to DEHP, have been associated with insulin resistance in adults, but have not been studied in adolescents."
"Urinary DEHP concentrations were associated with increased insulin resistance in this cross-sectional study of adolescents. This study cannot rule out the possibility that insulin-resistant children ingest food with higher phthalate content, or that insulin-resistant children excrete more DEHP."
SOURCE AND FOR FURTHER READING
PEDIATRICS - OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS